HC Wainwright Expects Stronger Earnings for Neurogene

Key Points

• HC Wainwright raised its FY2026 earnings forecast for Neurogene to a loss of $5.04 per share from a projected loss of $5.44, while maintaining a Buy rating and a $60 price target.
• Neurogene reported a quarterly loss of $1.05 per share, beating analyst expectations of a $1.36 loss by $0.31.
• Analyst sentiment is broadly positive: MarketBeat reports an average Buy rating and a consensus price target of $79.57, though ratings range from Strong Buy to Sell.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Investment analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Neurogene in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($5.04) per share for the year, up from their prior forecast of ($5.44). HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Neurogene's current full-year earnings is ($5.78) per share. HC Wainwright also issued estimates for Neurogene's Q4 2026 earnings at ($1.16) EPS, Q1 2027 earnings at ($1.18) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.22) EPS and FY2027 earnings at ($4.80) EPS.

Other equities research analysts also recently issued reports about the stock. William Blair raised shares of Neurogene to a "strong-buy" rating in a research report on Wednesday, September 23rd. Guggenheim boosted their price objective on Neurogene from $69.00 to $81.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. initiated coverage on Neurogene in a report on Thursday, October 8th. They issued an "overweight" rating and a $60.00 price target for the company. Canaccord Genuity Group cut their price objective on shares of Neurogene from $180.00 to $166.00 and set a "buy" rating for the company in a research report on Wednesday, August 12th. Finally, Wall Street Zen cut Neurogene from a "sell" rating to a "strong sell" rating in a research report on Saturday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $79.57.

Neurogene Price Performance

NGNE opened at $25.10 on Thursday. The firm's fifty day moving average price is $28.78 and its two-hundred day moving average price is $28.04. Neurogene has a 1 year low of $15.93 and a 1 year high of $43.66. The company has a market capitalization of $519.60 million, a price-to-earnings ratio of -4.93 and a beta of 1.75.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.31.

Hedge Funds Weigh In On Neurogene

A number of large investors have recently bought and sold shares of the stock. State of Wyoming purchased a new position in shares of Neurogene in the second quarter worth $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Neurogene in the third quarter worth $28,000. Legal & General Group Plc bought a new position in shares of Neurogene in the 2nd quarter worth about $35,000. China Universal Asset Management Co. Ltd. lifted its position in Neurogene by 45.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,651 shares of the company's stock valued at $104,000 after acquiring an additional 1,136 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Neurogene during the 2nd quarter valued at about $192,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company's lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.